Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
NDC API
0
VMF
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23h,25h-benzo(b)porphine-9,13-dipropanoic Acid Monomethyl Ester
2. Benzoporphyrin Derivative Monoacid Ring A
3. Bpd Verteporfin
4. Bpd-ma
5. Verteporfin
6. Verteporphin
1. Bpd Verteporfin
2. Bpd-ma(sub C)
3. Verteporfin C Isomer
4. Wu713d62n9
5. Verteporphin
6. Cl-315555
7. 133513-12-9
8. (1): 3-[(23s,24r)-14-ethenyl-5-(3-methoxy-3-oxopropyl)-22,23-bis(methoxycarbonyl)-4,10,15,24-tetramethyl-25,26,27,28-tetraazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-9-yl]propanoic Acid.
9. (2r,2(1)s)-8-ethenyl-2(1),2(2)-bis(methoxycarbonyl)-17-(3-methoxy-3-oxopropyl)-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13-propanoic Acid
10. (4s,4ar)-18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23h,25h-benzo[b]porphine-9,13-dipropanoic Acid 9-methyl Ester
11. 23h,25h-benzo(b)porphine-9,13-dipropanoic Acid, 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-, 9-monomethyl Ester, Trans-
12. 3-[(1z,6z,12z,17z,23s,24r)-14-ethenyl-22,23-bis(methoxycarbonyl)-5-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-25,26,27,28-tetraazahexacyclo[16.6.1.1(3,6).1(8,11).113,16.019,24]octacosa-1,3(28),4,6,8,10,12,14,16(26),17,19,21-dodecaen-9-yl]propanoic Acid
13. Bpd-ma-a1
14. Unii-0x9pa28k43
15. Verteporfin [usan:usp:inn:ban]
16. Verteporfin-mac
17. Verteporfin C5 Isomer
18. Schembl6219
19. (+-)-trans-3,4-dicarboxy-4,4a-dihydro-4a,8,14,19-tetramethyl-18-vinyl-23h,25h-benzo(b)porphine-9,13-dipropionic Acid, 3,4,9-trimethyl Ester Mixture With (+-)-trans-3,4-dicarboxy-4,4a-dihydro-4a,8,14,19-tetramethyl-18-vinyl-23h,25h-benzo(b)porphine-9,13-dipropionic Acid, 3,4,13-trimethyl Ester
20. Trans-3,4-dicarboxy-4,4a-dihydro-4a,8,14,19-tetramethyl-18-vinyl-23h,25h-benzo(b)porphine-9,13-dipropionic Acid 3,4,9-trimethyl Ester
21. Unii-wu713d62n9
22. Chembl2052016
23. Chembl3822934
24. Schembl14257223
25. Chebi:60775
26. Dtxsid30892511
27. 0x9pa28k43
28. Dtxsid001031353
29. Ex-a1344
30. Nsc836163
31. S1786
32. Ccg-270403
33. Db00460
34. Nsc-836163
35. Ncgc00346712-01
36. Ncgc00346712-02
37. 23h,25h-benzo(b)porphine-9,13-dipropanoic Acid, 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-, Monomethyl Ester, Trans-
38. Sw219955-1
39. J2.000.745a
40. Ab01566862_01
41. A899099
42. J-005685
43. (2r,21s)-2,21-dihydro-8-vinyl-2,7,12,18-tetramethyl-17-[2-(methoxycarbonyl)ethyl]-21,22-bis(methoxycarbonyl)-21h,23h-benzo[b]porphyrin-13-propionic Acid
44. (2r,21s)-8-ethenyl-2,21-dihydro-13-(3-hydroxy-3-oxopropyl)-17-(3-methoxy-3-oxopropyl)-2,7,12,18-tetramethyl-22h,24h-benzo[b]porphyrin-21,22-dicarboxylic Acid Dimethyl Ester
45. 3-[(23s,24r)-14-ethenyl-22,23-bis(methoxycarbonyl)-5-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-9-yl]propanoic Acid
46. 9-methyl-trans-18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23h,25h-benzo(b)porphine-9,13-dipropanoate,dl-
| Molecular Weight | 718.8 g/mol |
|---|---|
| Molecular Formula | C41H42N4O8 |
| XLogP3 | 4.9 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 12 |
| Exact Mass | 718.30026431 g/mol |
| Monoisotopic Mass | 718.30026431 g/mol |
| Topological Polar Surface Area | 174 Ų |
| Heavy Atom Count | 53 |
| Formal Charge | 0 |
| Complexity | 1500 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Visudyne |
| PubMed Health | Verteporfin (Injection) |
| Drug Classes | Photosensitizing Agent |
| Drug Label | Visudyne (verteporfin for injection) is a light activated drug used in photodynamic therapy. The finished drug product is a lyophilized dark green cake. Verteporfin is a 1:1 mixture of two regioisomers (I and II), represented by the following struc... |
| Active Ingredient | Verteporfin |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 15mg/vial |
| Market Status | Prescription |
| Company | Valeant Pharms |
| 2 of 2 | |
|---|---|
| Drug Name | Visudyne |
| PubMed Health | Verteporfin (Injection) |
| Drug Classes | Photosensitizing Agent |
| Drug Label | Visudyne (verteporfin for injection) is a light activated drug used in photodynamic therapy. The finished drug product is a lyophilized dark green cake. Verteporfin is a 1:1 mixture of two regioisomers (I and II), represented by the following struc... |
| Active Ingredient | Verteporfin |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 15mg/vial |
| Market Status | Prescription |
| Company | Valeant Pharms |
For the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis syndrome. Verteporfin can also be used to destroy tumors.
FDA Label
Visudyne is indicated for the treatment of:
- adults with exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or;
- adults with subfoveal choroidal neovascularisation secondary to pathological myopia.
Verteporfin, otherwise known as benzoporphyrin derivative, is a medication used in conjunction with laser treatment to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.
Photosensitizing Agents
Drugs that are pharmacologically inactive but when exposed to ultraviolet radiation or sunlight are converted to their active metabolite to produce a beneficial reaction affecting the diseased tissue. These compounds can be administered topically or systemically and have been used therapeutically to treat psoriasis and various types of neoplasms. (See all compounds classified as Photosensitizing Agents.)
S01LA01
Route of Elimination
Elimination is by the fecal route, with less than 0.01% of the dose recovered in urine.
Metabolized to a small extent to its diacid metabolite by liver and plasma esterases. NADPH-dependent liver enzyme systems (including the cytochrome P450 isozymes) do not appear to play a role in the metabolism of verteporfin.
Following intravenous infusion, verteporfin exhibits a bi-exponential elimination with a terminal elimination half-life of approximately 5-6 hours. Mild hepatic insufficiency increases half-life by approximately 20%.
Verteporfin is transported in the plasma primarily by lipoproteins. Once verteporfin is activated by light in the presence of oxygen, highly reactive, short-lived singlet oxygen and reactive oxygen radicals are generated. Light activation of verteporfin results in local damage to neovascular endothelium, resulting in vessel occlusion. Damaged endothelium is known to release procoagulant and vasoactive factors through the lipo-oxygenase (leukotriene) and cyclo-oxygenase (eicosanoids such as thromboxane) pathways, resulting in platelet aggregation, fibrin clot formation and vasoconstriction. Verteporfin appears to somewhat preferentially accumulate in neovasculature, including choroidal neovasculature. However, animal models indicate that the drug is also present in the retina. As singlet oxygen and reactive oxygen radicals are cytotoxic, Verteporfin can also be used to destroy tumor cells.
API SUPPLIERS
TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24377
Submission : 2010-11-04
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Co-Processed Excipients
Granulation
Direct Compression
Coating Systems & Additives
Controlled & Modified Release
Fillers, Diluents & Binders
Digital Content
DATA COMPILATION #PharmaFlow
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
